Columnar cell variant thyroid gland papillary carcinoma

Summary

Columnar cell variant thyroid gland papillary carcinoma (MONDO:0004102) is a cancer and 1 clinical trial. Top therapeutic interventions include lenvatinib. A subtype of thyroid gland papillary carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	columnar cell variant thyroid gland papillary carcinoma
Mondo ID	MONDO:0004102
DOID	DOID:7088
NCIT	C35830
UMLS	C1333120
MedGen	272499
GARD	0023823
Is cancer (heuristic)	yes

Also known as: columnar cell variant papillary carcinoma · columnar cell variant papillary thyroid gland carcinoma · columnar cell variant thyroid gland papillary carcinoma

Disease family

This is a subtype of thyroid gland papillary carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › papillary adenocarcinoma › thyroid gland papillary carcinoma › columnar cell variant thyroid gland papillary carcinoma

Related subtypes (5): thyroid gland diffuse sclerosing papillary carcinoma, multicentric papillary thyroid carcinoma, tall cell variant thyroid gland papillary carcinoma, thyroid gland papillary and follicular carcinoma, thyroid cancer, nonmedullary, 1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02973997	PHASE2	COMPLETED	Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LENVATINIB	4	2